Hostname: page-component-77f85d65b8-pztms Total loading time: 0 Render date: 2026-03-29T18:40:25.564Z Has data issue: false hasContentIssue false
  • English
  • Français

Behavioral activation therapy for depression is associated with a reduction in the concentration of circulating quinolinic acid

Published online by Cambridge University Press:  25 November 2020

Jonathan Savitz Open the ORCID record for Jonathan Savitz [Opens in a new window] ,
Bart N. Ford ,
Hung-Wen Yeh ,
Elisabeth Akeman ,
Kelly Cosgrove ,
Ashley N. Clausen ,
Christopher Martell ,
Namik Kirlic ,
Jessica Santiago  and
T. Kent Teague
...Show all authors
Jonathan Savitz*
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA Oxley College of Health Sciences, The University of Tulsa, Tulsa, OK, USA
Bart N. Ford
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA
Hung-Wen Yeh
Affiliation:
Childrens’ Mercy Hospital, Kansas City, MO, USA
Elisabeth Akeman
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA
Kelly Cosgrove
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA Department of Psychology, The University of Tulsa, Tulsa, OK, USA
Ashley N. Clausen
Affiliation:
Kansas City VA Healthcare System, Kansas City, MO, USA Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, MO, USA
Christopher Martell
Affiliation:
Department of Psychological and Brain Sciences, University of Massachusetts Amherst, Amherst, MO, USA
Namik Kirlic
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA
Jessica Santiago
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA
T. Kent Teague
Affiliation:
Department of Surgery, University of Oklahoma School of Community Medicine, Tulsa, OK, USA Department of Psychiatry, University of Oklahoma School of Community Medicine, Tulsa, OK, USA Department of Pharmaceutical Sciences, University of Oklahoma College of Pharmacy, Tulsa, OK, USA
Michael R. Irwin
Affiliation:
Cousins Center for Psychoneuroimmunology at UCLA, Semel Institute for Neuroscience and UCLA David Geffen School of Medicine, Los Angeles, CA, USA
Martin P. Paulus
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA Oxley College of Health Sciences, The University of Tulsa, Tulsa, OK, USA
Robin L. Aupperle*
Affiliation:
Laureate Institute for Brain Research, Tulsa, OK, USA Oxley College of Health Sciences, The University of Tulsa, Tulsa, OK, USA
*
Author for correspondence: Jonathan Savitz, E-mail: jsavitz@laureateinstitute.org, Robin Aupperle, E-mail: raupperle@laureateinstitute.org
Author for correspondence: Jonathan Savitz, E-mail: jsavitz@laureateinstitute.org, Robin Aupperle, E-mail: raupperle@laureateinstitute.org
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

An inflammation-induced imbalance in the kynurenine pathway (KP) has been reported in major depressive disorder but the utility of these metabolites as predictive or therapeutic biomarkers of behavioral activation (BA) therapy is unknown.

Methods

Serum samples were provided by 56 depressed individuals before BA therapy and 29 of these individuals also provided samples after 10 weeks of therapy to measure cytokines and KP metabolites. The PROMIS Depression Scale (PROMIS-D) and the Sheehan Disability Scale were administered weekly and the Beck depression inventory was administered pre- and post-therapy. Data were analyzed with linear mixed-effect, general linear, and logistic regression models. The primary outcome for the biomarker analyses was the ratio of kynurenic acid to quinolinic acid (KynA/QA).

Results

BA decreased depression and disability scores (p's < 0.001, Cohen's d's > 0.5). KynA/QA significantly increased at post-therapy relative to baseline (p < 0.001, d = 2.2), an effect driven by a decrease in QA post-therapy (p < 0.001, uncorrected, d = 3.39). A trend towards a decrease in the ratio of kynurenine to tryptophan (KYN/TRP) was also observed (p = 0.054, uncorrected, d = 0.78). Neither the change in KynA/QA, nor baseline KynA/QA were associated with response to BA therapy.

Conclusion

The current findings together with previous research show that electronconvulsive therapy, escitalopram, and ketamine decrease concentrations of the neurotoxin, QA, raise the possibility that a common therapeutic mechanism underlies diverse forms of anti-depressant treatment but future controlled studies are needed to test this hypothesis.

Keywords

Kynurenine pathwaymajor depressive disorderquinolinic acid

Information

Type
Original Article
Information
Psychological Medicine , Volume 52 , Issue 13 , October 2022 , pp. 2500 - 2509
Check for updates
Copyright
Copyright © The Author(s), 2020. Published by Cambridge University Press.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

‡

The online version of this article has been updated since original publication. A notice detailing the changes has also been published at https://doi.org/10.1017/S0033291721002683

References

Addis, M. E., & Martell, C. R. (2004). Overcoming depression one step at a time: The new behavioral activation approach to getting your life back. USA: New Harbinger Publications, Incorporated.Google Scholar
Bartfai, T., Sanchez-Alavez, M., Andell-Jonsson, S., Schultzberg, M., Vezzani, A., Danielsson, E., & Conti, B. (2007). Interleukin-1 system in CNS stress: Seizures, fever, and neurotrauma. Annals of the New York Academy of Sciences, 1113, 173–177. doi: 10.1196/annals.1391.022.CrossRefGoogle ScholarPubMed
Bartlett, S. J., Orbai, A. M., Duncan, T., DeLeon, E., Ruffing, V., Clegg-Smith, K., & Bingham, C. O., 3rd. (2015). Reliability and validity of selected PROMIS measures in people with rheumatoid arthritis. PLoS One, 10(9), e0138543. doi: 10.1371/journal.pone.0138543.CrossRefGoogle ScholarPubMed
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Traskman-Bendz, L., Guillemin, G. J., … Brundin, L. (2015). A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain, Behavior, and Immunity, 43, 110–117. doi: 10.1016/j.bbi.2014.07.012.CrossRefGoogle ScholarPubMed
Beck, A. T., Steer, R. A., Ball, R., & Ranieri, W. F. (1996a). Comparison of Beck depression inventories-IA and-II in psychiatric outpatients. Journal of personality assessment, 67(3), 588–597.CrossRefGoogle Scholar
Beck, A. T., Steer, R. A., & Brown, G. K. (1996 b). Beck depression inventory manual, 2nd Edn. San Antonio: Psychological Corporation.Google Scholar
Bernstein, C. N., Zhang, L., Lix, L. M., Graff, L. A., Walker, J. R., & Fisk, J. D., … Managing the Effects of Immune-mediated Inflammatory, D. (2018). The validity and reliability of screening measures for depression and anxiety disorders in inflammatory bowel disease. Inflammatory Bowel Disease, 24(9), 1867–1875. doi: 10.1093/ibd/izy068.CrossRefGoogle ScholarPubMed
Broderick, J. E., DeWitt, E. M., Rothrock, N., Crane, P. K., & Forrest, C. B. (2013). Advances in patient-reported outcomes: The NIH PROMIS measures. eGEMS, 1(1), 1015. doi: 10.13063/2327-9214.1015.CrossRefGoogle Scholar
Butler, A. C., Chapman, J. E., Forman, E. M., & Beck, A. T. (2006). The empirical status of cognitive-behavioral therapy: A review of meta-analyses. Clinical Psychology Review, 26(1), 17–31. doi: 10.1016/j.cpr.2005.07.003.CrossRefGoogle ScholarPubMed
Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., … Miller, A. H. (2007). Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology, 32(11), 2384–2392. doi: 10.1038/sj.npp.1301362.CrossRefGoogle ScholarPubMed
Capuron, L., Pagnoni, G., Drake, D. F., Woolwine, B. J., Spivey, J. R., Crowe, R. J., … Miller, A. H. (2012). Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Archives of General Psychiatry, 69(10), 1044–1053. doi: 10.1001/archgenpsychiatry.2011.2094.CrossRefGoogle ScholarPubMed
Castren, E. (2013). Neuronal network plasticity and recovery from depression. JAMA Psychiatry, 70(9), 983–989. doi: 10.1001/jamapsychiatry.2013.1.CrossRefGoogle ScholarPubMed
Cella, D., Riley, W., Stone, A., Rothrock, N., Reeve, B., Yount, S., … Group, P. C. (2010). The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. Journal of Clinical Epidemiology, 63(11), 1179–1194.CrossRefGoogle ScholarPubMed
Dahl, J., Ormstad, H., Aass, H. C., Sandvik, L., Malt, U. F., & Andreassen, O. A. (2016). Recovery from major depressive disorder episode after non-pharmacological treatment is associated with normalized cytokine levels. Acta Psychiatrica Scandinavica, 134(1), 40–47. doi: 10.1111/acps.12576.CrossRefGoogle ScholarPubMed
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008). From inflammation to sickness and depression: When the immune system subjugates the brain. Nature Reviews Neuroscience, 9(1), 46–56.CrossRefGoogle ScholarPubMed
de Bie, J., Lim, C. K., & Guillemin, G. J. (2016). Progesterone alters kynurenine pathway activation in IFN-gamma-activated macrophages - relevance for neuroinflammatory diseases. International Journal of trypTophan Research: IJTR, 9, 89–93. doi: 10.4137/IJTR.S40332.CrossRefGoogle ScholarPubMed
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., … Gallop, R. (2005). Cognitive therapy vs medications in the treatment of moderate to severe depression. Archives of General Psychiatry, 62(4), 409–416. doi: 10.1001/archpsyc.62.4.409.CrossRefGoogle ScholarPubMed
Deyo, R. A., Ramsey, K., Buckley, D. I., Michaels, L., Kobus, A., Eckstrom, E., … Morris, C. (2015). Performance of a patient reported outcomes measurement information system (PROMIS) short form in older adults with chronic musculoskeletal pain. Pain Medicine, 17(2), 314–324. doi: 10.1093/pm/pnv046.Google Scholar
Dimidjian, S., Barrera, M. Jr., Martell, C., Munoz, R. F., & Lewinsohn, P. M. (2011). The origins and current status of behavioral activation treatments for depression. Annual Review of Clinical Psychology, 7, 1–38. doi:10.1146/annurev-clinpsy-032210-104535.CrossRefGoogle ScholarPubMed
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., … Jacobson, N. S. (2006). Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. Journal of Consulting and Clinical Psychology, 74(4), 658–670. doi: 10.1037/0022-006X.74.4.658.CrossRefGoogle ScholarPubMed
Doering, L. V., Cross, R., Vredevoe, D., Martinez-Maza, O., & Cowan, M. J. (2007). Infection, depression, and immunity in women after coronary artery bypass: A pilot study of cognitive behavioral therapy. Alternative Therapies in Health and Medicine, 13(3), 18–21.Google ScholarPubMed
Doolin, K., Allers, K. A., Pleiner, S., Liesener, A., Farrell, C., Tozzi, L., … O'Keane, V. (2018). Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes. Psychoneuroendocrinology, 95, 8–17. doi: 10.1016/j.psyneuen.2018.05.019.CrossRefGoogle ScholarPubMed
Driessen, E., Van, H. L., Don, F. J., Peen, J., Kool, S., Westra, D., … Dekker, J. J. (2013). The efficacy of cognitive-behavioral therapy and psychodynamic therapy in the outpatient treatment of major depression: A randomized clinical trial. The American Journal of Psychiatry, 170(9), 1041–1050. doi: 10.1176/appi.ajp.2013.12070899.CrossRefGoogle ScholarPubMed
Eisenberger, N. I., Berkman, E. T., Inagaki, T. K., Rameson, L. T., Mashal, N. M., & Irwin, M. R. (2010). Inflammation-induced anhedonia: Endotoxin reduces ventral striatum responses to reward. Biological Psychiatry, 68(8), 748–754. doi: S0006-3223(10)00599-8 [pii].10.1016/j.biopsych.2010.06.010.CrossRefGoogle Scholar
Euteneuer, F., Dannehl, K., Del Rey, A., Engler, H., Schedlowski, M., & Rief, W. (2017). Immunological effects of behavioral activation with exercise in major depression: An exploratory randomized controlled trial. Translational Psychiatry, 7(5), e1132. doi: 10.1038/tp.2017.76.CrossRefGoogle ScholarPubMed
Felger, J. C., & Treadway, M. T. (2017). Inflammation effects on motivation and motor activity: Role of dopamine. Neuropsychopharmacology, 42(1), 216–241. doi: 10.1038/npp.2016.143.CrossRefGoogle ScholarPubMed
Finch, H. (2017). Multilevel modeling in the presence of outliers: A comparison of robust estimation methods. Psicologia, 38, 57–92.Google Scholar
Gazal, M., Souza, L. D., Fucolo, B. A., Wiener, C. D., Silva, R. A., Pinheiro, R. T., … Kaster, M. P. (2013). The impact of cognitive behavioral therapy on IL-6 levels in unmedicated women experiencing the first episode of depression: A pilot study. Psychiatry Research, 209(3), 742–745. doi: 10.1016/j.psychres.2013.03.002.CrossRefGoogle ScholarPubMed
Guillemin, G. J. (2012). Quinolinic acid, the inescapable neurotoxin. The FEBS Journal, 279(8), 1356–1365. doi: 10.1111/j.1742-4658.2012.08485.x.CrossRefGoogle ScholarPubMed
Halaris, A., Myint, A. M., Savant, V., Meresh, E., Lim, E., Guillemin, G., … Sinacore, J. (2015). Does escitalopram reduce neurotoxicity in major depression? Journal of Psychiatric Research, 66–67, 118–126. doi:10.1016/j.jpsychires.2015.04.026.CrossRefGoogle ScholarPubMed
Haroon, E., Welle, J. R., Woolwine, B. J., Goldsmith, D. R., Baer, W., Patel, T., … Miller, A. H. (2020). Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology, 45(6), 998–1007. doi: 10.1038/s41386-020-0607-1.CrossRefGoogle ScholarPubMed
Heyes, M. P., & Morrison, P. F. (1997). Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. Journal of Neurochemistry, 68(1), 280–288.CrossRefGoogle ScholarPubMed
Hitchon, C. A., Zhang, L., Peschken, C. A., Lix, L. M., Graff, L. A., Fisk, J. D., … Marrie, R. (2020). The validity and reliability of screening measures for depression and anxiety disorders in rheumatoid arthritis. Arthritis Care Research (Hoboken), 72(8), 1130–1139. doi: 10.1002/acr.24011.CrossRefGoogle ScholarPubMed
Howren, M. B., Lamkin, D. M., & Suls, J. (2009). Associations of depression with C-reactive protein, IL-1, and IL-6: A meta-analysis. Psychosomatic Medicine, 71(2), 171–186.CrossRefGoogle ScholarPubMed
Irwin, M. R., Olmstead, R., Breen, E. C., Witarama, T., Carrillo, C., Sadeghi, N., … Cole, S. (2015). Cognitive behavioral therapy and Tai Chi reverse cellular and genomic markers of inflammation in late-life insomnia: A randomized controlled trial. Biological Psychiatry, 78(10), 721–729. doi: 10.1016/j.biopsych.2015.01.010.CrossRefGoogle Scholar
Irwin, M. R., Olmstead, R., Carrillo, C., Sadeghi, N., Breen, E. C., Witarama, T., … Nicassio, P. (2014). Cognitive behavioral therapy vs. Tai Chi for late life insomnia and inflammatory risk: A randomized controlled comparative efficacy trial. Sleep, 37(9), 1543–1552. doi: 10.5665/sleep.4008.CrossRefGoogle ScholarPubMed
Kadriu, B., Farmer, C. A., Yuan, P., Park, L. T., Deng, Z. D., Moaddel, R., … Zarate, C. A. Jr. (2019). The kynurenine pathway and bipolar disorder: Intersection of the monoaminergic and glutamatergic systems and immune response. Molecular Psychiatry. doi: 10.1038/s41380-019-0589-8.Google ScholarPubMed
Keri, S., Szabo, C., & Kelemen, O. (2014). Expression of toll-like receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder. Brain Behavior and Immunity, 40, 235–243. doi: 10.1016/j.bbi.2014.03.020.CrossRefGoogle ScholarPubMed
Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. Nature Reviews Immunology, 16(10), 626–638. doi: 10.1038/nri.2016.90.CrossRefGoogle ScholarPubMed
Kruse, J. L., Congdon, E., Olmstead, R., Njau, S., Breen, E. C., Narr, K. L., … Irwin, M. R. (2018). Inflammation and improvement of depression following electroconvulsive therapy in treatment-resistant depression. Journal of Clinical Psychiatry, 79, 2. doi: 10.4088/JCP.17m11597.Google ScholarPubMed
Lynch, M. A. (2015). Neuroinflammatory changes negatively impact on LTP: A focus on IL-1beta. Brain Research, 1621, 197–204. doi: 10.1016/j.brainres.2014.08.040.CrossRefGoogle ScholarPubMed
Martell, C. R., Dimidjian, S., & Herman-Dunn, R. (2010). Behavioral activation for depression: A clinician's guide. New York, NY: Guilford Press.Google Scholar
Meier, T. B., Drevets, W. C., Teague, T. K., Wurfel, B. E., Mueller, S. C., Bodurka, J., … Savitz, J. (2018). Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression. Brain, Behavior, and Immunity, 67, 59–64. doi: 10.1016/j.bbi.2017.08.024.CrossRefGoogle ScholarPubMed
Meier, T. B., Drevets, W. C., Wurfel, B. E., Ford, B. N., Morris, H. M., Victor, T. A., … Savitz, J. (2016). Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain, Behavior, and Immunity, 53, 39–48. doi: 10.1016/j.bbi.2015.11.003.CrossRefGoogle ScholarPubMed
Moore, R. C., Chattillion, E. A., Ceglowski, J., Ho, J., von Kanel, R., Mills, P. J., … Mausbach, B. T. (2013). A randomized clinical trial of behavioral activation (BA) therapy for improving psychological and physical health in dementia caregivers: Results of the pleasant events program (PEP). Behavioral Research and Therapy, 51(10), 623–632. doi: 10.1016/j.brat.2013.07.005.CrossRefGoogle Scholar
Moreira, F. P., Cardoso Tde, A., Mondin, T. C., Souza, L. D., Silva, R., Jansen, K., … Wiener, C. D. (2015). The effect of proinflammatory cytokines in cognitive behavioral therapy. Journal of Neuroimmunology, 285, 143–146. doi: 10.1016/j.jneuroim.2015.06.004.CrossRefGoogle ScholarPubMed
Mura, G., Moro, M. F., Patten, S. B., & Carta, M. G. (2014). Exercise as an add-on strategy for the treatment of major depressive disorder: A systematic review. CNS Spectrums, 19(6), 496–508. doi: 10.1017/S1092852913000953.CrossRefGoogle ScholarPubMed
Myint, A. M., Kim, Y. K., Verkerk, R., Scharpe, S., Steinbusch, H., & Leonard, B. (2007). Kynurenine pathway in major depression: Evidence of impaired neuroprotection. Journal of Affective Disorders, 98(1–2), 143–151. doi: S0165-0327(06)00323-5 [pii].10.1016/j.jad.2006.07.013.CrossRefGoogle ScholarPubMed
O'Connor, J. C., Lawson, M. A., Andre, C., Moreau, M., Lestage, J., Castanon, N., … Dantzer, R. (2009). Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Molecular Psychiatry, 14(5), 511–522. doi: 10.1038/sj.mp.4002148.CrossRefGoogle ScholarPubMed
Olfson, M., & Marcus, S. C. (2010). National trends in outpatient psychotherapy. American Journal of Psychiatry, 167(12), 1456–1463. doi: 10.1176/appi.ajp.2010.10040570.CrossRefGoogle ScholarPubMed
Paoletti, P., Bellone, C., & Zhou, Q. (2013). NMDA Receptor subunit diversity: Impact on receptor properties, synaptic plasticity and disease. Nature Reviews Neuroscience, 14(6), 383–400. doi: 10.1038/nrn3504.CrossRefGoogle ScholarPubMed
Patterson, S. L. (2015). Immune dysregulation and cognitive vulnerability in the aging brain: Interactions of microglia, IL-1beta, BDNF and synaptic plasticity. Neuropharmacology, 96(Pt A), 11–18. doi: 10.1016/j.neuropharm.2014.12.020CrossRefGoogle ScholarPubMed
Pilkonis, P. A., Yu, L., Dodds, N. E., Johnston, K. L., Maihoefer, C. C., & Lawrence, S. M. (2014). Validation of the depression item bank from the patient-reported outcomes measurement information system (PROMIS) in a three-month observational study. Journal of Psychiatric Research, 56, 112–119. doi: 10.1016/j.jpsychires.2014.05.010.CrossRefGoogle Scholar
Pittenger, C., & Duman, R. S. (2008). Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology, 33(1), 88–109. doi: 10.1038/sj.npp.1301574.CrossRefGoogle Scholar
Romero-Sanchiz, P., Nogueira-Arjona, R., Araos, P., Serrano, A., Barrios, V., Argente, J., … Fonseca, F. R. (2020). Variation in chemokines plasma concentrations in primary care depressed patients associated with Internet-based cognitive-behavioral therapy. Scientific Reports, 10(1), 1078. doi: 10.1038/s41598-020-57967-y.CrossRefGoogle ScholarPubMed
Santiago, J., Akeman, E., Kirlic, N., Clausen, A. N., Cosgrove, K. T., McDermott, T. J., … Aupperle, R. L. (2020). Protocol for a randomized controlled trial examining multilevel prediction of response to behavioral activation and exposure-based therapy for generalized anxiety disorder. Trials, 21(1), 17. doi: 10.1186/s13063-019-3802-9.CrossRefGoogle ScholarPubMed
Savitz, J. (2020). The kynurenine pathway: A finger in every pie. Molecular Psychiatry, 25(1), 131–147. doi: 10.1038/s41380-019-0414-4.CrossRefGoogle ScholarPubMed
Savitz, J., Drevets, W. C., Smith, C. M., Victor, T. A., Wurfel, B. E., Bellgowan, P. S., … Dantzer, R. (2015a). Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology, 40(2), 463–471. doi: 10.1038/npp.2014.194.CrossRefGoogle Scholar
Savitz, J., Drevets, W. C., Wurfel, B. E., Ford, B. N., Bellgowan, P. S., Victor, T. A., … Dantzer, R. (2015b). Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain, Behavior, and Immunity, 46, 55–59. doi: 10.1016/j.bbi.2015.02.007.CrossRefGoogle Scholar
Schlittler, M., Goiny, M., Agudelo, L. Z., Venckunas, T., Brazaitis, M., Skurvydas, A., … Andersson, D. C. (2016). Endurance exercise increases skeletal muscle kynurenine aminotransferases and plasma kynurenic acid in humans. American Journal of Physiology: Cell Physiology, 310(10), C836–C840. doi: 10.1152/ajpcell.00053.2016.CrossRefGoogle ScholarPubMed
Schwieler, L., Samuelsson, M., Frye, M. A., Bhat, M., Schuppe-Koistinen, I., Jungholm, O., … Erhardt, S. (2016). Electroconvulsive therapy suppresses the neurotoxic branch of the kynurenine pathway in treatment-resistant depressed patients. Journal of Neuroinflammation, 13(1), 51. doi: 10.1186/s12974-016-0517-7.CrossRefGoogle ScholarPubMed
Sharpe, L., & Schrieber, L. (2012). A blind randomized controlled trial of cognitive versus behavioral versus cognitive-behavioral therapy for patients with rheumatoid arthritis. Psychotherapy and Psychosomatics, 81(3), 145–152. doi: 10.1159/000332334.CrossRefGoogle ScholarPubMed
Sharpley, C. F. (2010). A review of the neurobiological effects of psychotherapy for depression. Psychotherapy (Chic), 47(4), 603–615. doi: 10.1037/a0021177.CrossRefGoogle ScholarPubMed
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996). The measurement of disability. International Clinical Psychopharmacology, 11, 89–95.CrossRefGoogle ScholarPubMed
Sheehan, D. V., Lecrubier, Y., Sheehan, K. H., Amorim, P., Janavs, J., Weiller, E., … Dunbar, G. C. (1998). The Mini-international neuropsychiatric interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. Journal of Clinical Psychiatry, 59(Suppl 20), 22–33; quiz 34–57.Google ScholarPubMed
Shields, G. S., Spahr, C. M., & Slavich, G. M. (2020). Psychosocial interventions and immune system function: A systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry, 77(10), 1031–1043. doi: 10.1001/jamapsychiatry.2020.0431.CrossRefGoogle ScholarPubMed
Taylor, C. B., Conrad, A., Wilhelm, F. H., Strachowski, D., Khaylis, A., Neri, E., … Spiegel, D. (2009). Does improving mood in depressed patients alter factors that may affect cardiovascular disease risk? Journal of Psychiatric Research, 43(16), 1246–1252. doi: 10.1016/j.jpsychires.2009.05.006.CrossRefGoogle ScholarPubMed
Verdonk, F., Petit, A. C., Abdel-Ahad, P., Vinckier, F., Jouvion, G., de Maricourt, P., … Gaillard, R. (2019). Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. Brain, Behavior, and Immunity, 81, 361–373. doi: 10.1016/j.bbi.2019.06.033.CrossRefGoogle Scholar
Wurfel, B. E., Drevets, W. C., Bliss, S. A., McMillin, J. R., Suzuki, H., Ford, B. N., … Savitz, J. B. (2017). Serum kynurenic acid is reduced in affective psychosis. Translational Psychiatry, 7(5), e1115. doi: 10.1038/tp.2017.88.CrossRefGoogle ScholarPubMed
Yoshimura, R., Hori, H., Ikenouchi-Sugita, A., Umene-Nakano, W., Katsuki, A., Atake, K., & Nakamura, J. (2013). Plasma levels of interleukin-6 and selective serotonin reuptake inhibitor response in patients with major depressive disorder. Human Psychopharmacology, 28(5), 466–470. doi: 10.1002/hup.2333.CrossRefGoogle ScholarPubMed
Young, K. D., Drevets, W. C., Dantzer, R., Teague, T. K., Bodurka, J., & Savitz, J. (2016). Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression. Brain, Behavior, and Immunity, 56, 335–342. doi: 10.1016/j.bbi.2016.04.007.CrossRefGoogle ScholarPubMed
Yount, S. E., Beaumont, J. L., Chen, S. Y., Kaiser, K., Wortman, K., Van Brunt, D. L., … Cella, D. (2016). Health-related quality of life in patients with idiopathic pulmonary fibrosis. Lung, 194(2), 227–234. doi: 10.1007/s00408-016-9850-y.CrossRefGoogle ScholarPubMed
Zabihiyeganeh, M., Vafaee Afshar, S., Amini Kadijani, A., Jafari, D., Bagherifard, A., Janbozorgi, M., … Mirzaei, A. (2019). The effect of cognitive behavioral therapy on the circulating proinflammatory cytokines of fibromyalgia patients: A pilot controlled clinical trial. General Hospital Psychiatry, 57, 23–28. doi: 10.1016/j.genhosppsych.2019.01.003.CrossRefGoogle ScholarPubMed
Zahra, D., & Hedge, C. (2010). The reliable change index: Why isn't it more popular in academic psychology? Psychology Postgraduate Affairs Group Quarterly, 76, 14–19.Google Scholar
Zautra, A. J., Davis, M. C., Reich, J. W., Nicassario, P., Tennen, H., Finan, P., … Irwin, M. R. (2008). Comparison of cognitive behavioral and mindfulness meditation interventions on adaptation to rheumatoid arthritis for patients with and without history of recurrent depression. Journal of Consulting and Clinical Psychology, 76(3), 408–421. doi: 10.1037/0022-006X.76.3.408.CrossRefGoogle ScholarPubMed
Zhou, Y., Zheng, W., Liu, W., Wang, C., Zhan, Y., Li, H., … Ning, Y. (2018). Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. Brain, Behavior, and Immunity, 74, 205–212. doi: 10.1016/j.bbi.2018.09.007.CrossRefGoogle ScholarPubMed
Zunszain, P. A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A. M., … Pariante, C. M. (2012). Interleukin-1beta: A new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology, 37(4), 939–949. doi: 10.1038/npp.2011.277.CrossRefGoogle ScholarPubMed
Supplementary material: File

Savitz et al. supplementary material

Savitz et al. supplementary material

Download Savitz et al. supplementary material(File)
File 32.6 KB